Skip to main content

Structure Therapeutics Inc.

GPCR
Exchange
Nasdaq
Industry
Pharmaceutical Preparations
SEC CIK
0001888886

No open-market purchases or sales by Structure Therapeutics Inc. insiders were filed in the last 90 days; 191 institutions reported holding it in 13F filings for Q2 2026, worth $3.62B in total; no superinvestor holds it.

Open-market trades, last 90 days

Open-market purchases (P) and sales (S) by Structure Therapeutics Inc. insiders, counted by Form 4 filing. Trades with a flagged price and duplicate filings are left out.

Open-market buys
0 filings
Open-market sells
0 filings
Insiders trading
0
Net value
$0
Purchases minus sales

Insider roster

Directors, officers and 10% owners who have filed a Form 4 for Structure Therapeutics Inc., current and former, most recent filer first. Last reported holding is the position after the last non-derivative trade in their latest filing.

Insider roster for Structure Therapeutics Inc.
NameTitleLast reported holdingLast filingFilings, past year
Coll Crespo BlasCHIEF MEDICAL OFFICER258,228Sep 22, 20263
Lin XichenCHIEF SCIENTIFIC OFFICER228,960Sep 2, 20267
Berrios John JosephChief Commercial Officer140,766Aug 7, 20261
FMR LLC10% Owner, Other: See Remark 14,769,404IndirectJul 24, 20264
Love Ted WDirector–Jun 18, 20261
Dobmeier EricDirector–Jun 18, 20261
Welch Daniel GDirector123,508IndirectJun 18, 20261
Tetlow SharonDirector–Jun 18, 20261
Russell Angus C.Director–Jun 18, 20261
Waldstreicher JoanneDirector–Jun 18, 20261
Lang MatthewCOO & GC184,614Apr 23, 20261
Stevens Raymond CCHIEF EXECUTIVE OFFICER1,401,593Mar 23, 20262
Hall AshleyChief Development Officer155,187Mar 23, 20262
Yoon JunCHIEF FINANCIAL OFFICER1,401,656Mar 23, 20262
Ma YingliCHIEF TECHNOLOGY OFFICER139,917Mar 23, 20262
Bach Mark AllenCHIEF MEDICAL OFFICER26,235Mar 20, 20240
Biotechnology Value Fund L POther: See explanation of responses0May 12, 20230
BVF Partners L P10% Owner0May 12, 20230
BVF Inc10% Owner0May 12, 20230
Biotechnology Value Fund II LPOther: See explanation of responses0May 12, 20230
Lampert Mark N10% Owner0May 12, 20230
Biotechnology Value Trading Fund OS LPOther: See explanation of responses0May 12, 20230
BVF Partners OS Ltd.Other: See explanation of responses0May 12, 20230
BVF I GP LLCOther: See explanation of responses0May 12, 20230
BVF II GP LLCOther: See explanation of responses0May 12, 20230
BVF GP Holdings LLC10% Owner0May 12, 20230
FIL LtdOther: See Remark 1624,239IndirectFeb 9, 20230
Farid RamyDirector3,260,495IndirectFeb 9, 20230
Jung Melita SunChief Business Officer–Feb 9, 20230

Insider trades

Each row adds up one type of transaction in one Form 4 filing. Only open-market purchases (P) and sales (S) are shown by default; use the filters to see grants, option exercises and other codes.

Insider trades
Filed (ET)Trade dateFiling delayInsiderTransactionSharesAvg priceValueHolding changeFlags
Sep 22, 2026 (view filing)5:59 PM ETSep 211 dayColl Crespo BlasCHIEF MEDICAL OFFICERSSale−12.0K$36.15−$434.6K–1.16K afterDerivative10b5-1
Sep 2, 2026 (view filing)9:18 PM ETSep 11 dayLin XichenCHIEF SCIENTIFIC OFFICERSSale−5.94K$46.92−$278.7K–0 afterDerivative3 lots10b5-1
Aug 19, 2026 (view filing)8:23 PM ETAug 181 dayLin XichenCHIEF SCIENTIFIC OFFICERSSale−11.8K$17.82−$210.6K–0 afterDerivative3 lots10b5-1
Aug 5, 2026 (view filing)4:49 PM ETAug 41 dayLin XichenCHIEF SCIENTIFIC OFFICERSSale−11.8K$16.48−$194.8K–0 afterDerivative2 lots10b5-1
Jul 24, 2026 (view filing)9:11 AM ETJul 222 daysFMR LLC10% Owner, Other: See Remark 1SSale−52.4K$16.69−$873.8K–16.1K afterDerivative2 lots
Jul 15, 2026 (view filing)6:57 PM ETJul 141 dayLin XichenCHIEF SCIENTIFIC OFFICERSSale−23.6K$16.99−$401.6K–0 afterDerivative2 lots10b5-1
Jun 29, 2026 (view filing)8:32 PM ETJun 254 daysLin XichenCHIEF SCIENTIFIC OFFICERSSale−23.6K$16.36−$386.6K–0 afterDerivative10b5-1
Apr 16, 2026 (view filing)Apr 142 daysFMR LLC10% Owner, Other: See Remark 1SSale−52.4K$18.36−$961.1K–32.2K afterDerivative2 lots
Jan 20, 2026 (view filing)Jan 155 daysFMR LLC10% Owner, Other: See Remark 1SSale−52.4K$27.77−$1.45M–48.3K afterDerivative8 lots
Dec 10, 2025 (view filing)Dec 82 daysFMR LLC10% Owner, Other: See Remark 1SSale−157.1K$23.99−$3.77M–0 afterDerivative10 lots
Aug 1, 2025 (view filing)Jul 302 daysFMR LLC10% Owner, Other: See Remark 1SSale−78.9K$5.96−$470.2K–1.52M afterDerivative
Feb 10, 2025 (view filing)Feb 64 daysFMR LLC10% Owner, Other: See Remark 1SSale−123$10.18−$1.25K–0 afterDerivative
Jun 12, 2024 (view filing)Jun 102 daysStevens Raymond CCHIEF EXECUTIVE OFFICERSSale−555.0K$17.60−$9.77M–0 afterDerivative
Jun 5, 2024 (view filing)7:38 PM ETJun 32 daysLin XichenCHIEF SCIENTIFIC OFFICERSSale−106.2K$15.83−$1.68M–0 afterDerivative2 lots10b5-1
Mar 18, 2024 (view filing)Mar 144 daysFMR LLC10% Owner, Other: See Remark 1SSale−66.0K$11.67−$769.9K–1.54M afterDerivative
Feb 15, 2024 (view filing)Feb 132 daysFMR LLC10% Owner, Other: See Remark 1SSale−1.57K$15.75−$24.8K–1.56M afterDerivative
Dec 7, 2023 (view filing)Dec 52 daysFMR LLC10% Owner, Other: See Remark 1SSale−52.4K$20.82−$1.09M–32.2K afterDerivative2 lots
Oct 23, 2023 (view filing)Oct 185 daysLateFMR LLC10% Owner, Other: See Remark 1SSale−52.4K$21.88−$1.15M–48.3K afterDerivative2 lots
Feb 9, 2023 (view filing)Feb 72 daysFarid RamyDirectorPPurchase+825.0K$5.00+$4.13M–275.0K afterDerivative
Feb 9, 2023 (view filing)Feb 72 daysJung Melita SunChief Business OfficerPPurchase+3.00K$5.00+$15.0K–1.00K afterDerivative
Feb 9, 2023 (view filing)Feb 72 daysBach Mark AllenChief Medical OfficerPPurchase+4.50K$5.00+$22.5K–1.50K afterDerivative
Feb 9, 2023 (view filing)Feb 72 daysYoon JunChief Financial OfficerPPurchase+1.80K$5.00+$9.00K–600 afterDerivative
Feb 9, 2023 (view filing)Feb 72 daysStevens Raymond CChief Executive OfficerPPurchase+12.0K$5.00+$60.0K–4.00K afterDerivative